Third Rock fuels $41M launch of Bay Area biotech

Global Blood Therapeutics presents one of the latest examples of using advances in computer technology to build value in drug discovery. Recently launched with a $40.7 million round of funding from Third Rock Ventures, the biotech startup plans to harness the power of its tech platform--called SHAPE--to combat blood diseases. The company is combining computational biology and protein-ligand modeling with medicinal chemistry and "empiric screening capabilities focused on allosteric modulation." The goal of the effort is to create oral drugs that can alter the shape of blood proteins to treat disorders such as sickle cell disease. Article

Suggested Articles

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.

TriNetX's platform uses EHR data to help drug developers with clinical trial protocol design and study site and participant identification.

The $58 million financing round represents biopharma industry's growing interest in genomics data.